Insomnia - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 93 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Insomnia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Insomnia - Pipeline Review, H2 2014', provides an overview of the Insomnia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Insomnia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insomnia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Insomnia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Insomnia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Insomnia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Insomnia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Insomnia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Insomnia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Insomnia Overview 9
Therapeutics Development 10
Pipeline Products for Insomnia - Overview 10
Pipeline Products for Insomnia - Comparative Analysis 11
Insomnia - Therapeutics under Development by Companies 12
Insomnia - Therapeutics under Investigation by Universities/Institutes 14
Insomnia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Insomnia - Products under Development by Companies 18
Insomnia - Products under Investigation by Universities/Institutes 19
Insomnia - Companies Involved in Therapeutics Development 20
Actelion Ltd 20
Angelini Group 21
Eisai Co., Ltd. 22
Evotec AG 23
Grupo Ferrer Internacional, S.A. 24
Heptares Therapeutics Ltd. 25
Intec Pharma ltd. 26
Intra-Cellular Therapies, Inc. 27
Jiangsu Nhwa Pharma Corporation 28
Johnson & Johnson 29
Merck & Co., Inc. 30
Minerva Neurosciences, Inc. 31
Neurim Pharmaceuticals Ltd 32
Novartis AG 33
Reviva Pharmaceuticals Inc. 34
Rottapharm SpA 35
Somnus Therapeutics, Inc. 36
Takeda Pharmaceutical Company Limited 37
Insomnia - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 46
ACT-462206 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CR-5542 Series - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
E-2006 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
EVT-201 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ITI-007 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
JNJ-42847922 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
LASSBio-785 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
LASSBio-786 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
lorediplon - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MIN-202 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Orexin Receptor Antagonist for Insomnia - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
piromelatine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ramelteon - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
RP-15000 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Small Molecule to Agonize GABA-A for Insomnia - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecule to Antagonize Orexin 1/2 for Insomnia - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecule to Inhibit OX2R for Insomnia - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
suvorexant - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
trazodone hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
UCM-765 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
zaleplon DR - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
zaleplon GR - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Insomnia - Recent Pipeline Updates 73
Insomnia - Dormant Projects 81
Insomnia - Discontinued Products 82
Insomnia - Product Development Milestones 83
Featured News & Press Releases 83
Sep 22, 2014: Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial 83
Aug 13, 2014: FDA Approves BELSOMRA for the Treatment of Insomnia 83
Jul 01, 2013: Merck Receives Complete Response Letter for Suvorexant, Merck's Investigational Medicine for Insomnia 85
May 22, 2013: Merck Wins FDA Panel Recommendation For Insomnia Drug Suvorexant At Lower Dose 86
May 20, 2013: Merck's Experimental Insomnia Drug Safe But May Carry Troublesome Side Effects, FDA Staff Says 86
Apr 03, 2013: Merck's Insomnia Drug Suvorexant Induces Sleep With Fewer Side Effects, Preclinical Study Shows 87
Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia 87
Nov 28, 2012: New Drug May Offer New Approach To Treating Insomnia, Study Finds 88
Nov 08, 2012: Merck Announces FDA Acceptance Of New Drug Application For Suvorexant 89
Sep 10, 2012: Merck Announces New Phase III Data For Investigational Insomnia Medicine Suvorexant 89
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 93
Disclaimer 93

List of Tables
Number of Products under Development for Insomnia, H2 2014 10
Number of Products under Development for Insomnia - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Insomnia - Pipeline by Actelion Ltd, H2 2014 20
Insomnia - Pipeline by Angelini Group, H2 2014 21
Insomnia - Pipeline by Eisai Co., Ltd., H2 2014 22
Insomnia - Pipeline by Evotec AG, H2 2014 23
Insomnia - Pipeline by Grupo Ferrer Internacional, S.A., H2 2014 24
Insomnia - Pipeline by Heptares Therapeutics Ltd., H2 2014 25
Insomnia - Pipeline by Intec Pharma ltd., H2 2014 26
Insomnia - Pipeline by Intra-Cellular Therapies, Inc., H2 2014 27
Insomnia - Pipeline by Jiangsu Nhwa Pharma Corporation, H2 2014 28
Insomnia - Pipeline by Johnson & Johnson, H2 2014 29
Insomnia - Pipeline by Merck & Co., Inc., H2 2014 30
Insomnia - Pipeline by Minerva Neurosciences, Inc., H2 2014 31
Insomnia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2014 32
Insomnia - Pipeline by Novartis AG, H2 2014 33
Insomnia - Pipeline by Reviva Pharmaceuticals Inc., H2 2014 34
Insomnia - Pipeline by Rottapharm SpA, H2 2014 35
Insomnia - Pipeline by Somnus Therapeutics, Inc., H2 2014 36
Insomnia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 37
Assessment by Monotherapy Products, H2 2014 38
Number of Products by Stage and Target, H2 2014 40
Number of Products by Stage and Mechanism of Action, H2 2014 42
Number of Products by Stage and Route of Administration, H2 2014 44
Number of Products by Stage and Molecule Type, H2 2014 45
Insomnia Therapeutics - Recent Pipeline Updates, H2 2014 73
Insomnia - Dormant Projects, H2 2014 81
Insomnia - Discontinued Products, H2 2014 82